Impact of Cellular Immune Function on Prognosis of Lung Cancer Patients after Cytokine-induced Killer Cell Therapy |
Jin, Congguo
(Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University))
Li, Jia (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) Wang, Yeying (Epidemiology and Biostatistics Department, School of Public Health, Kunming Medical University) Chen, Xiaoqun (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) Che, Yanhua (Breast Disease Center, The First Peoples' Hospital of Kunming, Yunnan Province) Liu, Xin (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) Wang, Xicai (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) Sriplung, Hutcha (Epidemiology Unit, Faculty of Medicine, Prince of Songkla University) |
1 | Dougan M, Dranoff G (2009). Immune therapy for cancer. Annu Rev Immunol, 27, 83-117. DOI ScienceOn |
2 | Hontscha C, Borck Y, Zhou H, et al (2011). Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 137, 305-10. DOI |
3 | Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. A Cancer J Clin, 61, 69-90. DOI |
4 | Jiang J, Xu N, Wu C, et al (2006). Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res, 11, 2237-42. |
5 | Jiang JT, Shen YP, Wu CP, et al (2010). Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol, 11, 6155-62. |
6 | Jin CG, Chen XQ, Li J, et al (2013). Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy. Asian Pac J Cancer Prev, 14, 6229-34. |
7 | Blattman JN, Greenberg PD (2004). Cancer immunotherapy: a treatment for the masses. Science, 305, 200-5. DOI ScienceOn |
8 | Chen W, Zhang R, Zhang S, et al (2013). The incidences and mortalities of major cancers in China, 2009. Chin J Cancer, 32, 106-12. DOI |
9 | Kim HM, Lim J, Park SK, et al (2007). Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol, 7, 1802-7. DOI ScienceOn |
10 | Li R, Wang C, Liu L, et al (2012). Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 61, 2125-33. DOI ScienceOn |
11 | Lin J, Zhu H, Lu X, et al (2010). Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses. Intern Med, 49, 2341-6. DOI |
12 | Olioso P, Giancola R, Di Riti M, et al (2009). Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 11, 130-9. |
13 | Schmidt-Wolf IG, Finke S, Trojaneck B, et al (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer, 11, 1009-16. |
14 | Schmidt-Wolf IG, Lefterova P, Mehta BA, et al (1993). Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol, 21, 1673-9. |
15 | Schmidt-Wolf IG, NR, Kiem HP, et al (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokineinduced killer cells with potent antitumor cell activity. J Exp Med, 174, 139-49. DOI ScienceOn |
16 | Stroncek D, Berlyne D, Fox B, et al (2010). Developments in clinical cell therapy. Cytotherapy, 12, 425-8. DOI ScienceOn |
17 | Zhong R, Han B, Zhong H (2013). A prospective study of the efficacy of a combination of autologous endritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol, [Epub ahead of print]. |
18 | Sun Y, Liao M, Cheng G (2011). NCCN nonsmall-cell lung cancer clinical practice guidline:Chinese edition vesion. Beijing. |
19 | Wu C, Jiang J, Shi L, et al (2008). Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res, 11, 3997-4002. |
20 | Zheng YW, Li RM, Zhang XW, et al (2013). Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest, 31, 197-205. DOI ScienceOn |